We are live on ! Find out more
PR

Payden & Rygel Portfolio holdings

AUM $1.3B
1-Year Est. Return 28.32%
This Fund
S&P 500
This Quarter Est. Return
+2.88%
1 Year Est. Return
+28.32%
3 Year Est. Return
+89.13%
5 Year Est. Return
+123.15%
10 Year Est. Return
+353.66%
AUM
$1.69B
AUM Growth
-$187M
Cap. Flow
-$186M
Cap. Flow %
-11.04%
Top 10 Hldgs %
22.67%
Holding
154
New
18
Increased
32
Reduced
44
Closed
32

Top Buys

Rank Stock Value
1
DOX icon
Amdocs
DOX
+$36M
2
PG icon
Procter & Gamble
PG
+$24.9M
3
GLW icon
Corning
GLW
+$18.7M
4
CARR icon
Carrier Global
CARR
+$17.4M
5
DD icon
DuPont de Nemours
DD
+$17.2M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$36.2M
2
MET icon
MetLife
MET
+$32.7M
3
HYG icon
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
+$30.6M
4
PAYX icon
Paychex
PAYX
+$27.6M
5
ADM icon
Archer Daniels Midland
ADM
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 16.45%
2 Technology 14.49%
3 Financials 13.6%
4 Industrials 10.79%
5 Consumer Staples 10.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXE
151
Expand Energy Corp
EXE
$21.6B
– –
-215,300
Closed -$20.3M
3 4 5 6
7

Similar funds

GPCM
Greenbrier Partners Capital Management Dallas, Texas $1.3B AUM 21.43% 1-Year Est. Return
PWP
Private Wealth Partners Mill Valley, California $1.3B AUM 26.2% 1-Year Est. Return
MCM
Mainstay Capital Management Grand Blanc, Michigan $1.3B AUM 37.8% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
HCS
Himension Capital (Singapore) Singapore $1.3B AUM 85.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SP
Sherman Porfolios Coeur D'alene, Idaho $1.3B AUM 35.18% 1-Year Est. Return
CCFM
Clear Creek Financial Management Silverdale, Washington $1.3B AUM 20.31% 1-Year Est. Return

Payden & Rygel's Q1 2023 Portfolio in Review

As of Q1 2023, Payden & Rygel held 154 positions worth $1.69B, down 10% from $1.88B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Payden & Rygel withdrew a net $186M in Q1 2023, closing 32 positions and reducing 44 holdings. Its most notable exit was Paychex, an estimated $27.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 19% a quarter earlier, followed by Technology and Financials.

Against the trend, Payden & Rygel opened a new position in Amdocs worth $37.4M.

  • Payden & Rygel's largest Q1 2023 buy was Amdocs: 389,000 shares worth $37.4M.
  • Payden & Rygel added most to DuPont de Nemours in Q1 2023, an estimated $17.2M increase.
  • Payden & Rygel's biggest Q1 2023 reduction was CVS Health, cutting an estimated $36.2M.
  • Payden & Rygel fully exited Paychex in Q1 2023, selling an estimated $27.6M.
  • Payden & Rygel's ten largest holdings make up 23% of its $1.69B portfolio in Q1 2023.
  • Payden & Rygel opened 18 new positions and closed 32 in Q1 2023.
  • Payden & Rygel's portfolio value fell 10% quarter-over-quarter to $1.69B.

Based on Payden & Rygel's 13F filing for Q1 2023, filed 10 May 2023.